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BiosensorBecause of the high heterogeneity of breast cancer (BC), BC subtype-speciﬁc biomarker panel might be
useful for diagnostic BC or becomes an adjunct assay to improve the accuracy of current screening meth-
ods. In this study, we measured the protein levels of human epidermal receptor-2 extracellular domain
(HER2 ECD) and total prostate-speciﬁc antigen (t-PSA) in the serum from 14 BC patients and 8 healthy
controls by utilizing our previously developed high-throughput metal-enhanced ﬂuorescence biosensor.
The experimental results showed that the summation of HER2 ECD and t-PSA serum levels is proposed in
this study. We found that AUC >0.9 of better ability to distinguish HER2+ group from HER2 and healthy
groups. In the mean time, if taking the ratio of t-PSA and HER2 ECD serum levels, it is very useful able to
differentiate HER2 group from HER2+ and healthy groups at value of AUC >0.8. To our best knowledge,
this is for the ﬁrst time to integrate serum levels of HER2 ECD and t-PSA levels potentially suggested in
the screening BC patients for further improving the speciﬁcity by using our developed high-throughput
metal-enhanced ﬂuorescence biosensor.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Breast cancer (BC) is one of the most progressive cancers world-
wide and the annular increased rate of BC patients is more than 2%
both in the developed and developing countries recent years. In
order to improve survival rates, selection of diagnostic and prog-
nostic factors are both of the key decisions in the current manage-
ment of BC [1,2], and the use of serum biomarkers as the diagnostic
or prognostic factor seems the most convenient method. However,
imaging techniques such as ultrasound, mammography and MRI
are still the most frequently used approaches on diagnosis or fol-
lowup for BC patients until now. This is because that the complex-
ities of morphological and molecular distinct entities of BC, thereare presently no single serum biomarker available highly sensitive
and speciﬁc detection on BC in early-stage or minimal disease
recurrence based on immunoassay diagnostic setup [3,4]. In addi-
tion, most of serum biomarkers exhibit low speciﬁcity causing can-
cer diagnosis based on single serum biomarker possesses lower
reliability [5,6]. For instance, carcinoembryonic antigen (CEA) is
known as a biomarker for both digestive system cancers and BC.
Therefore, multi-markers detection for a speciﬁc cancer diagnosis
can be applicable for cancer screening tool and may play an extre-
mely important role [5–9]. A consensus has coalesced around the
idea that effective and accurate detection of early-stage cancer will
likely rely on biomarker panel rather than a single biomarker that
possess better speciﬁcity and sensitivity [7–9]. Thus, if an assay
based on multi-serum biomarker levels detection, whether BC
diagnostic or prognostic factor, will become highly desired and
anticipated in hospital and national public health program on
breast cancer prevention for women.
Because of the diversiform phenotype of BC, only biomarker
panel should be expected and is available for BC diagnosis. Thus,
BC subtype-speciﬁc biomarker panel might be appropriate for
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racy of current screening methods [10]. According to the American
Society of Clinical Oncology (ASCO), clinically to measure human
epidermal receptor-2 (HER2) level is needed tobe evaluated in every
primary invasive BC on diagnosis, or prognosis for patients on recur-
rence by metastatic BC [11,12]. HER2 overexpression has been
reported in over 20% sufferers of BC, which is associated with poor
prognosis and is alsopredictiveof response to someanticancer treat-
ments [11]. For instance, patients with HER2 positive disease have
increased response to adjuvant anthracycline-based treatment. In
addition, several targeted therapies, such as the trastuzumab, have
been developed speciﬁcally to treat patients with HER2-positive
BC [11]. Current methods used to identify the status of HER2, such
as immunohistochemistry (IHC), ﬂuorescent in situ hybridization
(FISH), and chromogenic in-situ hybridization (CISH), are invasive
and time-consumingbecauseof tissue acquisitionvia biopsy.Never-
theless, the shed HER2 extracellular domain (HER2 ECD) can be
detected in serum alternative of the biopsy. This is because of
HER2 ECD dependents on tumor HER2 status and tumor burden at
the time of assay. Normally the concentration of HER2 ECD in serum
is in the range of 15–20 ng/mL in healthy women [11] and becomes
one of the potential BC subtype-speciﬁc biomarkers in the panel.
Meanwhile, total prostate-speciﬁc antigen (t-PSA) can be suggested
tobeanotherpotential BC subtype-speciﬁcbiomarker in thepanel. It
can be found via synthesized and secreted by different human
organs including thebreast [13]. Several lines of evidencehave dem-
onstrated that t-PSA is not only a potential biomarker for breast can-
cer disease [14–17], but alsomayact as a regulator of cellular growth
factors or a mediator of endogenous hormone balance between
androgens,progesteroneandestrogens [18–20].However, it is asked
for the measuring concentration of t-PSA in women serum at high
detection sensitivity by the limit of detection (LOD) at 1 pg/mL due
to low concentration of t-PSA in women serum. Nevertheless, it is
very difﬁcult to reach by using existing technology such as ELISA.
As results, the application of probing t-PSA as biomarker for BC diag-
nosis in serum becomes much limited [21,22].
Because commercially available immunoassay presents limited
detection sensitivity on detecting low-abundance cancer biomark-
ers against the background of high-abundance plasma proteins.
Recently, gold nanomaterials (GNPs) show unique optical proper-
ties and high surface areas, which have been used to improve
LOD of biosensors [23–29]. GNPs not only can produce localized
ﬁeld which is signiﬁcantly ampliﬁed through localized surface
plasmons (LSPs) excitation, but also can generate a larger quantum
yield of ﬂuorescence emission due to increasing the radiative decay
rate of ﬂuorophore over 1000-fold, theoretically [30]. These cause
the emission of a ﬂuorophore near a GNP being much more
enhanced than that in free-space condition; the phenomenon is
called metal-enhanced ﬂuorescence (MEF) [31]. Based on the opti-
cal properties, we previously proposed and developed an MEF bio-
sensor in order to study protein–protein interactions at ultralow
concentration in the range of pg/mL level [4,32–39]. Moreover,
the mechanism of ﬂuorescence enhancement using metallic nano-
particles in this biosensor was studied too based on scattering the-
ory [40]. In this research, we use the proposed MEF biosensor to
measure HER2 ECD levels and t-PSA levels in human serum sam-
ples. To combine HER2 ECD and t-PSA serum levels for diagnostic
BC with different subtypes was discussed.2. Material and methods
2.1. Materials
This study was approved by the institutional review board of
Taipei City Hospital, Renai Branch under TCHIRB-991101-E. Thewritten consent was obtained from all participants. All the serum
samples were prepared by Dr. MD Shuo-Hui Hung of Department
of Surgery, Taipei City Hospital, Renai Branch, Taipei, Taiwan.
Totally 22 patients were recruited during the period from April
to June of 2010 in Taipei City Hospital, Renai Branch, Taipei,
Taiwan. Among them, 14 patients were diagnosed to be early BC
pre-treatment patients and 8 healthy females of no malignancy
noted after one year follow-up. From each individual, 2 mL fasting
peripheral blood was collected into BD (Biosciences, Franklin
Lakes, NJ, USA) tubes without anticoagulant. For cancer patients,
blood was collected before surgery. The blood was centrifuged at
3000g for 10 min at room temperature, and serum was then
stocked in 0.5 mL aliquots and stored at 80 C.
All BC diagnoses were conﬁrmed based on pathological exami-
nation. The status of HER2 was determined by immunohistochem-
istry (IHC) or ﬂuorescence in-situ hybridization (FISH). IHC staining
of specimens was carried out on formalin-ﬁxed parafﬁn-embedded
tissues using the polyclonal rabbit HER2 antibody (A0485; DAKO)
at a dilution of 1:400, and a peroxidase-conjugated detection sys-
tem (DAKO). FISH was ordered when HER2 IHC staining was scored
as weak positive (1+), or moderate positive (2+).
Meanwhile, the rabbit polyclonal anti-human t-PSA antibody,
which is used as both the capture antibody and detection antibody
in order to detect t-PSA in the serum samples, was purchased from
Meridian Life Science, Inc. (Memphis, TN, USA). In addition, the
rabbit polyclonal anti-human HER2 ECD antibody which was pur-
chased from Abnova (Taipei, Taiwan) is used as both capture anti-
body and detection antibody on the detection of HER2 ECD too. The
bovine serum albumin (BSA) and phosphate-buffered saline (PBS)
were bought from Sigma (St. Louis, MO, USA). Additionally, GNP-
conjugated streptavidin (Au-SA, GNP diameter 25 nm) was pro-
vided from Aurion (Wageningen, Netherlands). Finally, the ﬂuores-
cence labeling kit (Lightning-Link Atto633) and biotin labeling kit
were provided from Innova Biosciences (Cambridge, UK). In this
setup, 96-well immunoplates were used and they were from Corn-
ing Costar (Corning, NY, USA).
2.2. Preparation of the GNP probes
Biotin- and ﬂuorophore-labeled detection antibodies bound to
Au-SA was used as a GNP probe, as shown in Supplementary
Fig. S1. The detection antibody was conjugated to biotin and the
ﬂuorophore using commercial labeling kits from Innova Biosci-
ences. The ﬂuorophore (Lightning-Link Atto633) showed strong
absorption at 629 nm and a maximum ﬂuorescence emission at
657 nm. To produce the GNP probes, 2 lg/mL of the biotin- and
ﬂuorophore-labeled detection antibody was mixed with Au-SA at
a concentration of 8.5  109 particles/mL and then incubated for
more than 10 h at 4 C in the dark.
2.3. Optical setup and use of the biosensor
The optical setup of the biosensor is shown in Supplementary
Fig. S1. A two-frequency laserwith a 632.8 nmwavelengthwas used
as an excitation light source. This laser outputs a pair of orthogonal
linear polarization with a slight difference in the temporal
frequency (2 kHz), which can be generated using a frequency-
stabilized linear polarized He–Ne laser associated with an electro-
optical modulator that is driven by a 2 kHz sawtooth signal [41].
There is a beam splitter to split the two-frequency laser beam into
a signal beam and a reference beam. The signal beam is incident
to a single well of the 96-well immunoplate in which the <capture
antibody/target antigen/GNP probe> immunocomplex is constructed,
as shown in Supplementary Fig. S1. GNP probes are then excited by
the two-frequency laser beam, and a harmonic intensity-modulated
ﬂuorescence signal is generated via heterodyne interference. Two
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duced to this setup to detect the harmonic-modulated ﬂuorescence
signal via a photomultiplier tube. Simultaneously, the demodulated
intensities of the harmonic-modulated ﬂuorescence signal and the
heterodyned reference signal are obtained independently using
two lock-in ampliﬁers. The ratio of the demodulated ﬂuorescence
signal and the reference signal is monitored during measurement
in order to reduce the excess noise of the laser beam.
2.4. Measurement of t-PSA and HER2 ECD in diluted serum samples
Brieﬂy, 96-well immunoplates were ﬁrst coated with 50 lL of
6 lg/mL (300 ng/well) capture antibody at 4 C overnight. They
were then washed six times with PBS buffer. After the immuno-
plates were blocked with 100 lL of 1% BSA in PBS buffer (1%
BSA–PBS) for 1 h at 37 C, 10-fold-diluted serum samples in a total
volume of 100 lL were separately added in the wells, and the
plates were incubated at room temperature for 2 h. The immuno-
plates were then washed six times with PBS buffer again. Finally,
100 lL of the GNP probe solution was added to each well, followed
by a 2 h incubation at room temperature to form the <capture anti-
body/target antigen/GNP probe> immunocomplex on the bottom
surface of each well, as shown in Supplementary Fig. S1. After
washing six times with PBS buffer, the immunoplates were mea-
sured by the proposed MEF biosensor. This assay is conducted in
parallel using a conventional 96-well immunoplate, requiring a
scanning time of 15 minutes for all 96 samples.
3. Data analysis
3.1. p-Value
p-Value represents the probability which the result of statistical
testing is by chance. Usually, p-value less than 0.01 (or 0.05) indi-
cates a signiﬁcant difference between experiment and control
group.
3.2. Receiver operating characteristic (ROC) curve
We prepared ROC curves for the experimental data, using the
web-based programs (kindly provided by John Eng ROC analysis,
web-based calculator for ROC curves, Johns Hopkins University,
Baltimore, MD, USA; http://www.jrocﬁt.org) for ﬁtting ROC curves.Fig. 1. (A) Serum HER2 ECD levels in healthy controls (healthy, n = 8) were compared to th
ROC curve analyses of the ability of HER2 ECD to discriminate between HER2+ group anThe ROC curve is a graphical plot of the true positive (sensitivity)
versus false positive rate (1-speciﬁcity) for a binary classiﬁcation
system as its discrimination threshold is varied. Furthermore, each
point on the ROC curve corresponds to a unique pair of values for
sensitivity and speciﬁcity. The area under the ROC curve (AUC) is a
factor for measuring the performance of a test. The larger the AUC,
the better performance of the medical test correctly identify dis-
eased and non-diseased subjects. Normally, the value of AUC larger
than 0.7, 0.8 and 0.9 means acceptable, good and excellent,
respectively.4. Results and discussion
4.1. HER2 ECD serum level of BC patients and healthy controls
We detected the protein levels of HER2 ECD in the serum sam-
ples from 14 patients with BC (8 of HER2+ and 6 of HER2) and 8
healthy controls who were inspected via IHC and FISH previously,
using the proposed MEF biosensor. The measured results were pre-
sented based on normalized HER2 ECD level that was deﬁned as
the measured ﬂuorescence intensity of each well normalized with
that of positive controls in the same plate. We compared the means
of serum HER2 ECD between BC patients and healthy adults using
the normalized HER2 ECD level measured by the biosensor. The
results showed that the amount of serum HER2 ECD was signiﬁ-
cantly higher in HER2+ group than in the HER2 group
(p = 0.0067; Fig. 1A). Additionally, not only the HER2+ group but
also healthy group showed the amount of serum HER2 ECD is
higher than that in the HER2 group (p = 0.0389; Fig. 1A). The
mean and median values of normalized HER2 ECD levels in the
HER2 group are at 0.46 and 0.39, respectively (shown in
Fig. 1A). They are lower than those in the HER2+ group at 0.95
and 1.02, respectively and also the healthy group at 0.82 and
0.88, respectively. These data are reported in Table 1. In contrast,
there is no signiﬁcant difference between the HER2+ group and
the healthy controls (p = 0.2481; Fig. 1A) in this experiment. In
Fig. 1B, the empirical and ﬁtting ROC curve for serum HER2 ECD
level is able to distinguish between HER2+ and HER2 groups
apparently. Their empirical and ﬁtting AUC is 0.937 and 0.951,
respectively. Once a criterion value of normalized HER2 ECD level
greater than 0.70, the sensitivity and speciﬁcity are 83.3% and
87.5%, respectively. To compare our results with results of previous
research on HER2 diagnostic use HER2 ECD serum levels, bothose in BC patients HER2+ group (HER2+, n = 8) and HER2 group (HER2, n = 6). (B)
d HER2 group.
Table 1
Normalized HER2 ECD serum level of BC patients and healthy control group.
Breast cancer patients Healthy
group
HER2+
group
HER2
group
Number of samples 8 6 8
Normalized HER2 ECD
level
Mean 0.95 0.46 0.82
Median 1.02 0.39 0.88
Table 2
Normalized t-PSA serum level of BC patients and healthy control group.
Breast cancer patients Healthy
group
HER2+
group
HER2
group
Total
Number of
samples
8 6 14 8
Normalized t-PSA
level
Mean 0.77 0.67 0.72 0.53
Median 0.79 0.68 0.78 0.46
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status of tumor tissue is the most important tumor characteristics
to compare with HER2 ECD serum level. Establishment of these
characteristics can identify patients who will have a particularly
aggressive form of BC or who is eligible on treatment by HER2-tar-
geted therapy [11]. A high correlation between HER2 status of
tumor tissue and increasing HER2 ECD serum level were found in
our experimental results. These indicate that the HER ECD serum
level could be used as a potential biomarker enabling to discrimi-
nate HER2+ from HER2 groups in clinics. However, to ﬁnd a way
for distinguishing BC patents (including HER2+ and HER2) from
healthy group should be more important than to differentiate
HER2+ from HER2 in BC patients. This is the reason why we pro-
posed to associate t-PSA with HER2 ECD levels in serum sample for
improving performance on diagnosis of BC in clinics.4.2. Serum level of t-PSA in BC patients and healthy controls
Simultaneously, the concentration levels of t-PSA in serum sam-
ples were also measured by using the developed biosensor. Again,
the results were presented by using the normalized t-PSA level
which is deﬁned as the measured ﬂuorescence intensity in each
well and then normalized by that of positive controls in the same
plate. We compared the mean values of normalized t-PSA level
between BC patients (including HER2+ and HER2) and healthy
adults as shown in Fig. 2A. Although Fig. 2A shows that the
normalized t-PSA levels have no signiﬁcant difference in HER2+,
HER2 and healthy group, the normalized t-PSA levels presents a
fair differentiation between BC patients and healthy groupFig. 2. (A) Serum t-PSA levels in healthy controls (healthy, n = 8) were compared to th
patients (HER2+ and HER2, n = 14). (B) ROC curve analyses of the ability of t-PSA to d(p = 0.0760). Both the mean and median values of normalized t-
PSA levels in group of BC patients are 0.72 and 0.78, respectively.
They are higher than those in the healthy group at 0.53 and 0.46,
respectively as reported in Table 2. As a result, Fig. 2B shows the
empirical and ﬁtting ROC curve for normalized t-PSA level and is
able to distinguish the group of BC patients and healthy control.
Their empirical and ﬁtting AUC are 0.732 and 0.722, respectively,
and the criterion value of normalized t-PSA level greater than
0.49 results in the sensitivity and speciﬁcity at 78.6% and 62.5%,
respectively. These results are consistent with previous research
in BC diagnostic assays using different potential biomarkers, such
as mammaglobin, basic ﬁbroblast growth factor, and anti-malignin
antibody [3,43,44]. Our results show similar performance on sensi-
tivity and speciﬁcity.
4.3. Combination of HER2 ECD and t-PSA serum levels on BC diagnosis
There seems to be a growing consensus that panels of markers
may be able to supply better speciﬁcity and sensitivity than that by
using individual biomarker [5–9]. In addition, BC subtype-speciﬁc
biomarker panels can be a potential candidate for diagnosis of BC
or becoming an adjunct assay to improve the accuracy of current
screening methods [10]. As a result, summation of HER2 ECD and
t-PSA serum levels together therefore become one of the algo-
rithms of diagnostic factor-1 (DF-1) based on performance of the
normalized HER2 ECD and normalized t-PSA serum levels by using
the MEF biosensor. We compared the means of DF-1 among HER2+
BC subtype group and the HER2 BC subtype group and also
healthy control group. They show that the value of DF-1 is signiﬁ-
cantly higher in HER2+ BC subtype group than that in the otherose in HER2+ group (HER2+, n = 8), HER2 group (HER2, n = 6) and all of the BC
iscriminate BC patients from healthy controls.
Fig. 3. (A) The addition of HER2 ECD serum level and t-PSA serum level together as the diagnostic factor-1 (DF-1) in HER2+ group (n = 8) was compared to that in HER2
group and healthy controls (HER2 and healthy, n = 14). (B) ROC curve analyses of the ability of DF-1 to discriminate HER2+ group from HER2 group and healthy controls.
Table 3
Diagnostic factor-1 (DF-1) of HER2+ group and other two groups together.
Other groups
(HER2 group and
healthy group)
HER2+
group
Number of samples 14 8
Diagnostic factor-1 (DF-1)
(normalized HER2 ECD
level + normalized t-PSA level)
Mean 1.25 1.72
Median 1.32 1.80
Y.-F. Chang et al. / Sensing and Bio-Sensing Research 2 (2014) 1–7 5two groups (p = 0.0204; Fig. 3A). Both the mean and median values
of DF-1 in the HER2+ BC subtype (1.72 and 1.80, respectively) are
higher than those in the other two groups together (1.25 and
1.32, respectively) as reported in Table 3. Fig. 3B shows the empir-
ical and ﬁtting ROC curve for DF-1 to differentiate HER2+ BC sub-Fig. 4. (A) The ratio of HER2 ECD serum level to t-PSA serum level as the diagnostic factor
controls (HER2+ and healthy, n = 16). (B) ROC curve analyses of the ability of DF-2 to ditype group from other two groups. The empirical and ﬁtting AUC
are 0.804 and 0.821, respectively. In this analysis, the criterion
value of DF-1 greater than 1.62 means the sensitivity and speciﬁc-
ity at 75.0% and 86.4%, respectively.
Meanwhile, the ratio of normalized t-PSA level to normalized
HER2 ECD level is second potentially algorithm for the diagnostic
factor-2 (DF-2) in order to discriminate HER2 group from
HER2+ and healthy control groups. We compared the means of
DF-2 between HER2 BC subtype group and other two groups
together which include HER2+ group and healthy control group.
The results show that the amount of DF-2 is signiﬁcantly higher
in HER2 BC subtype group than one in other two groups together
(p < 0.005; Fig. 4A). Both the mean and median values of DF-2 in
the HER2 BC subtype are 1.66 and 1.67, respectively which are
lower than those in the other two groups together (0.77 and
0.77, respectively) as reported in Table 4. Fig. 4B shows the empir--2 (DF-2) in HER2 group (n = 6) was compared to that in HER2+ group and healthy
scriminate HER2 group from HER2+ group and healthy controls.
Table 4
Diagnostic factor-2 (DF-2) of HER2 group and other two groups together.
Other groups
(HER2+ group and
healthy group)
HER2
group
Number of samples 16 6
Diagnostic factor-2 (DF-2)
(normalized t-PSA level/
normalized HER2 ECD level)
Mean 0.77 1.66
Median 0.77 1.67
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HER2 BC subtype and other two groups. The empirical and ﬁtting
AUC are 0.917 and 0.921, respectively. In this analysis, the criterion
value of DF-2 greater than 1.01 means the sensitivity and speciﬁc-
ity at 83.3% and 81.2%, respectively.
Conventionally, the most effective approach for BC screening
method is based on X-ray mammography whereas AUC is esti-
mated in a range from 0.76 to 0.82 in clinical diagnosis. In order
to improve the accuracy of early detection of BC, the serum bio-
marker panel test was suggested [10,45,46]. However, high heter-
ogeneity of BC tumor leads to the situation of not possible on single
biomarker validated and incorporated in clinical early diagnosis of
BC to date [47–49]. Thus, the analysis of combining several poten-
tial serum biomarkers following proper designed algorithm
become a possible way to increase speciﬁcity and sensitivity for
breast cancer diagnosis. This will show advantages over single bio-
marker alone because of cross correlation of those biomarkers on
BC induction both biochemically and physiologically [5–9]. In addi-
tion to that, BC subtype-speciﬁc biomarker panels could be appli-
cable for detecting BC or used in an adjunct assay to improve the
sensitivity and speciﬁcity of current screening methods via imag-
ing [10]. According to the best of our knowledge, there was no
direct biological relationship between HER2 ECD and t-PSA. How-
ever, the complexity of cancer metabolism and heterogeneity of
BC cell are very complicated in their pathway during BC progres-
sion and this becomes much difﬁcult to be diagnosed at earlier
stage [50,51]. This is because the diversity of cancer cell should
inﬂuence the growth and decay of different biomarkers simulta-
neously due to their biochemical cross correlation dependence in
cancer biology.
5. Conclusions
In this study, we detected the protein levels of HER2 ECD and t-
PSA in the serum samples simultaneously utilizing our previously
developed MEF biosensor. The signiﬁcant association between
the HER2 status of tumor tissue and the raised HER2 ECD serum
level were identiﬁed in this study. Our experimental results indi-
cate that the HER ECD serum level could be used for the discrimi-
nation between HER2+ and HER2 groups. Simultaneously, our
preliminary data also shows that the measuring of serum t-PSA
levels is possible for the discrimination between the preoperative
BC patients (including HER2+ and HER2 BC subtypes) and the
healthy group, because the empirical and ﬁtting AUC are both
greater than 0.7. In addition, our preliminary results show that
simultaneous monitoring HER2 ECD and t-PSA serum levels exhib-
its higher AUCs for distinguishing HER2+ BC subtype from HER2
and healthy control groups together (DF-1, AUC > 0.9) and also able
to differentiate HER2 BC subtype from HER2+ and healthy control
groups together (DF-2, AUC > 0.8). These results indicate that BC
subtypes relates to the speciﬁc serum biomarkers of BC and this
preliminary study potentially can be introduced a direction on BC
diagnosis based on association of HER2-ECD and t-PSA serum lev-
els as a screening biomarker panel for BC.Conﬂict of interest
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